Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Dilated cardiomyopathy (DCM) is a condition in which the heart’s ability to pump blood is decreased because the heart’s main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in the legs, ankles, and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse, and metabolic disorders, such as thyroid disease or diabetes.
The dilated cardiomyopathy – drugs in development report provides an overview of the dilated cardiomyopathy pipeline landscape. It provides comprehensive information on the therapeutics under development for dilated cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated cardiomyopathy and features dormant and discontinued projects.
What are the key targets in the dilated cardiomyopathy pipeline products market?
The key targets in the dilated cardiomyopathy pipeline products market are BAG Family Molecular Chaperone Regulator 3, High Mobility Group Protein B1, Histone Deacetylase 6, Mitogen Activated Protein Kinase 14, Myosin, Prostacyclin Receptor, and Protein S100 A8.
Dilated Cardiomyopathy Pipeline Products by Targets
For more target insights, download a free report sample
What are the key mechanisms of action in the dilated cardiomyopathy pipeline products market?
The key mechanisms of action in the dilated cardiomyopathy pipeline products market are BAG Family Molecular Chaperone Regulator 3 Activator, High Mobility Group Protein B1 Activator, Histone Deacetylase 6 Inhibitor, Mitogen Activated Protein Kinase 14 Inhibitor, Myosin Activator, Prostacyclin Receptor Agonist, and Protein S100 A8 Activator.
Dilated Cardiomyopathy Pipeline Products by Mechanism of Action
For more mechanism of actions insights, download a free report sample
What are the key routes of administration in the dilated cardiomyopathy pipeline products market?
The key routes of administration in the dilated cardiomyopathy pipeline products market are intravenous, oral, intracoronary, intracardiac, intrapericardial, intravenous bolus, parenteral, and topical.
Dilated Cardiomyopathy Pipeline Products by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the dilated cardiomyopathy pipeline products market?
The different molecule types in the dilated cardiomyopathy pipeline products market are gene therapy, cell therapy, small molecule, antisense oligonucleotide, aptamer, and peptide.
Dilated Cardiomyopathy Pipeline Products by Molecule Type
To know more about molecule types, download a free report sample
Which are the major companies in the dilated cardiomyopathy pipeline products market?
The major companies in the dilated cardiomyopathy pipeline products market are DiNAQOR AG, Renovacor Inc, Bristol-Myers Squibb Co, Tenaya Therapeutics Inc, Avery Therapeutics Inc, Berlin Cures Holding AG, BioMarin Pharmaceutical Inc, BridgeBio Pharma Inc, Cardior Pharmaceuticals GmbH, and Celixir Ltd.
Dilated Cardiomyopathy Pipeline Products by Companies
To know more about major companies, download a free report sample
Market Report Scope
| Key targets | BAG Family Molecular Chaperone Regulator 3, High Mobility Group Protein B1, Histone Deacetylase 6, Mitogen Activated Protein Kinase 14, Myosin, Prostacyclin Receptor, and Protein S100 A8 |
| Key mechanism of action | BAG Family Molecular Chaperone Regulator 3 Activator, High Mobility Group Protein B1 Activator, Histone Deacetylase 6 Inhibitor, Mitogen Activated Protein Kinase 14 Inhibitor, Myosin Activator, Prostacyclin Receptor Agonist, and Protein S100 A8 Activator |
| Key routes of administration | Intravenous, Oral, Intracoronary, Intracardiac, Intrapericardial, Intravenous Bolus, Parenteral, and Topical |
| Molecule type | Gene Therapy, Cell Therapy, and Small Molecule, Antisense Oligonucleotide, Aptamer, and Peptide |
| Major companies | DiNAQOR AG, Renovacor Inc, Bristol-Myers Squibb Co, Tenaya Therapeutics Inc, Avery Therapeutics Inc, Berlin Cures Holding AG, BioMarin Pharmaceutical Inc, BridgeBio Pharma Inc, Cardior Pharmaceuticals GmbH, and Celixir Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of dilated cardiomyopathy (cardiovascular).
- The pipeline guide reviews pipeline therapeutics for dilated cardiomyopathy (cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in dilated cardiomyopathy (cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates dilated cardiomyopathy (cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for dilated cardiomyopathy (cardiovascular).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for dilated cardiomyopathy (cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding dilated cardiomyopathy (cardiovascular) pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Berlin Cures Holding AG
BioMarin Pharmaceutical Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
Cardior Pharmaceuticals GmbH
Celixir Ltd
CellServe GmbH
DiNAQOR AG
Dynomics Inc
Heartseed Inc
Help Therapeutics
iHeart Japan Corp
Martin Pharmaceuticals Inc
Maze Therapeutics Inc
NeoProgen Inc
Nuevocor Pte Ltd
Olagenesis Corp
Pfizer Inc
Recursion Pharmaceuticals Inc
Renovacor Inc
Shionogi & Co Ltd
Tenaya Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the dilated cardiomyopathy pipeline products market?
The key targets in the dilated cardiomyopathy pipeline products market are BAG Family Molecular Chaperone Regulator 3, High Mobility Group Protein B1, Histone Deacetylase 6, Mitogen Activated Protein Kinase 14, Myosin, Prostacyclin Receptor, and Protein S100 A8.
-
What are the key mechanisms of action in the dilated cardiomyopathy pipeline products market?
The key mechanisms of action in the dilated cardiomyopathy pipeline products market are BAG Family Molecular Chaperone Regulator 3 Activator, High Mobility Group Protein B1 Activator, Histone Deacetylase 6 Inhibitor, Mitogen Activated Protein Kinase 14 Inhibitor, Myosin Activator, Prostacyclin Receptor Agonist, and Protein S100 A8 Activator.
-
What are the key routes of administration in the dilated cardiomyopathy pipeline products market?
The key routes of administration in the dilated cardiomyopathy pipeline products market are intravenous, oral, intracoronary, intracardiac, intrapericardial, intravenous bolus, parenteral, and topical.
-
What are the different molecule types in the dilated cardiomyopathy pipeline products market?
The different molecule types in the dilated cardiomyopathy pipeline products market are gene therapy, cell therapy, small molecule, antisense oligonucleotide, aptamer, and peptide.
-
Which are the major companies in the dilated cardiomyopathy pipeline products market?
The major companies in the dilated cardiomyopathy pipeline products market are DiNAQOR AG, Renovacor Inc, Bristol-Myers Squibb Co, Tenaya Therapeutics Inc, Avery Therapeutics Inc, Berlin Cures Holding AG, BioMarin Pharmaceutical Inc, BridgeBio Pharma Inc, Cardior Pharmaceuticals GmbH, and Celixir Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Cardiovascular reports